A rare presentation of thyroid malignant peripheral nerve sheath tumor in neurofibromatosis type 1 delineated by FDG PET/CT: A case report and literature review

Document Type : Case report

Authors

1 Nuclear Medicine Department, King Hussein Cancer Center, Jordan

2 Department of Pathology, King Hussein Cancer Center, Amman, Jordan

Abstract

Malignant peripheral nerve sheath tumors (MPNST) are rare, aggressive soft tissue sarcomas that arise from peripheral nerves and often present a diagnostic and therapeutic challenge. They can occur sporadically or in association with neurofibromatosis type 1 (NF1), a genetic disorder caused by mutations in the NF1 gene. This report presents the unique case of a 33-year-old male with progressive dry cough, hoarseness, and neck swelling who underwent a total thyroidectomy, revealing a high-grade malignant peripheral nerve sheath tumor invading the thyroid. FDG PET/CT led to the additional diagnosis of NF1. This case stands out due to the rarity of finding an MPNST within the thyroid and the simultaneous identification of NF1. It underscores the importance of screening MPNST patients for NF1 and vice versa, spotlighting the expanding role of FDG PET/CT in comprehensive evaluations. To our knowledge, this report presents the first case of NF1-associated MPNST with thyroid involvement worldwide.

Keywords

Main Subjects

References

  1. Gupta G, Mammis A, Maniker A. Malignant Peripheral Nerve Sheath Tumors. Neurosurgery Clinics of North America. 2008; 19(4):533-43.
  2. Knight SWE, Knight TE, Santiago T, Murphy AJ, Abdelhafeez AH. Malignant Peripheral Nerve Sheath Tumors-A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management. Children (Basel). 2022; 9(1).
  3. Farid M, Demicco EG, Garcia R, Ahn L, Merola PR, Cioffi A, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014; 19(2):193-201.
  4. Pulliam S, Madwani K, Fox AD, El-Hachoum N, Ullah A, Patel N, et al. Metastatic Malignant Peripheral Nerve Sheath Tumor (MPNST) in Neurofibromatosis Type 1: Challenges in Diagnosis and Management. Cureus. 2022; 14(6):e26140.
  5. Kar M, Deo SVS, Shukla NK, Malik A, DattaGupta S, Mohanti BK, et al. Malignant peripheral nerve sheath tumors (MPNST) – Clinicopathological study and treatment outcome of twenty-four cases. World Journal of Surgical Oncology. 2006; 4(1):55.
  6. Arshi A, Tajudeen BA, St John M. Malignant peripheral nerve sheath tumors of the head and neck: Demographics, clinicopathologic features, management, and treatment Oral Oncol. 2015; 51(12):1088-94.
  7. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021; 113(2):70-84.
  8. Amirian ES, Goodman JC, New P, Scheurer ME. Pediatric and adult malignant peripheral nerve sheath tumors: an analysis of data from the surveillance, epidemiology, and end results program. J Neurooncol. 2014; 116(3):609-16.
  9. Salem RH, Almutairi OT, Bafaquh MS. Multifocal malignant peripheral nerve sheath tumor in patients with neurofibromatosis type I: Report of two cases and review of literature. Surg Neurol Int. 2023; 14: 261.
  10. Chen G, Liu Z, Su C, Guan Q, Wan F, Dong B, et al. Primary peripheral nerve sheath tumors of the thyroid gland: A case report and literature review. Mol Clin Oncol. 2016; 4(2):209-10.
  11. Balcerzak W, Dorobisz A, Czopnik P, editors. Malignant peripheral sheath tumour of the neck mimicking a thyroid tumour. A case report and a literature review from a reference centre for endocrine surgery2017.
  12. Treglia G, Taralli S, Bertagna F, Salsano M, Muoio B, Novellis P, et al. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with neurofibromatosis type 1: a systematic review. Radiol Res Pract. 2012; 2012: 431029.
  13. Khiewvan B, Macapinlac HA, Lev D, McCutcheon IE, Slopis JM, Al Sannaa G, et al. The value of ¹⁸F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. Eur J Nucl Med Mol Imaging. 2014; 41(9):1756-66.
  14. Tovmassian D, Abdul Razak M, London K. The Role of [(18)F]FDG-PET/CT in Predicting Malignant Transformation of Plexiform Neurofibromas in Neuro-fibromatosis-1. Int J Surg Oncol. 2016; 2016:6162182.
  15. Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging. 2009; 36(5):751-7.
  16. Broski SM, Johnson GB, Howe BM, Nathan MA, Wenger DE, Spinner RJ, et al. Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors. Skeletal Radiol. 2016; 45(8):1097-105.
  17. Yadav D, Shamim SA, Rastogi S, Upadhyay DMR, Pandey AK, Kumar R. Role of 18F-FDG PET/computed tomography in prognosti-ation and management of malignant peripheral nerve sheath tumors. Nucl Med Commun. 2020; 41(9): 924-32.
  18. Van Lierop Z, Jentjens S, Anten M, Wierts R, Stumpel CT, Havekes B, et al. Thyroid Gland (18)F-FDG Uptake in Neurofibromatosis Type 1. Eur Thyroid J. 2018; 7(3):155-61.
  19. Nishida Y, Ikuta K, Ito S, Urakawa H, Sakai T, Koike H, et al. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/ longitudinal study. Cancer Sci. 2021; 112(3):1114-22.
Asia Oceania Journal of Nuclear Medicine and Biology
Volume 12, Issue 2
July 2024
Pages 174-178

Files

Share

How to cite

Statistics